| Business Summary | | Quintiles
Transnational
Corp.
is
engaged
in
providing
a
full
range
of
integrated
product
development
and
commercial
development
solutions
to
the
pharmaceutical,
biotechnology
and
medical
device
industries.
The
Company
provides
market
research
solutions
and
strategic
analyses
to
support
healthcare
decisions
and
healthcare
policy
consulting
to
governments
and
other
organizations
worldwide.
The
Company
provides
a
broad
range
of
contract
services
to
help
its
clients
reduce
the
length
of
time
from
the
beginning
of
development
to
peak
sales
of
a
new
drug
or
medical
device.
Its
product
development
services
include
a
full
range
of
services
focused
on
helping
its
clients
through
the
development
and
regulatory
approval
of
a
new
drug
or
medical
device.
Its
commercial
development
services
focus
on
helping
its
clients
achieve
commercial
success
for
a
new
product
or
medical
device.
In
addition,
Quintiles
offers
healthcare
policy
research
and
management
consulting. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Quintiles
Transnational
is
engaged
in
the
provision
of
full-service
contract
research,
sales
and
marketing
and
healthcare
policy
consulting
services
to
the
global
pharmaceutical,
biotechnology
and
medical
device
industries.
For
the
six
months
ended
6/30/01,
revenues
fell
3%
to
$808.8
million.
Net
income
from
continuing
operations
totalled
$17.5
million
vs.
a
loss
of
$45.4
million.
Revenues
reflect
lower
contract
service
offerings.
Earnings
reflect
reduced
restructuring
charges. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Dennis Gillings, Ph.D, 56 Chairman | $1.2M | $481K | Pamela Kirby, Ph.D., 47 CEO | -- | -- | Santo Costa, 55 Vice
Chairman | 856K | 65K | James Bierman, 48 CFO | 266K | -- | Jim Kever, 48 Director
and CEO of ENVOY | 388K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|